Win Kyaw Z, Armstrong Matthew J, Steeds Richard P, Kalla Manish
Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust Birmingham, UK.
Institute of Cardiovascular Science, University of Birmingham Birmingham, UK.
Arrhythm Electrophysiol Rev. 2025 May 19;14:e09. doi: 10.15420/aer.2024.45. eCollection 2025.
Obesity independently increases AF risk and negatively affects the outcomes of catheter ablation. This review examines the relationship between obesity and AF, focusing on structural and electrical remodelling. Multiple studies demonstrate worse ablation outcomes in patients with obesity. Pre-ablation weight loss improves outcomes and maintaining weight loss post-ablation is equally important. Risk factor modification programmes show promise, however they require a large investment in resources. Less intensive strategies focusing on diet and exercise have shown mixed results. Glucagon-like peptide-1 receptor agonists have been identified as potential adjunct therapies. They have multiple effects, including preferential reduction of epicardial adipose tissue and an anti-inflammatory action. Further research is needed to establish their efficacy in improving ablation outcomes. This review highlights the importance of weight management in AF treatment and suggests potential monitoring strategies using cardiac imaging. Future studies may shift the paradigm for the management of AF patients with obesity who are undergoing ablation.
肥胖独立增加房颤风险,并对导管消融结果产生负面影响。本综述探讨肥胖与房颤之间的关系,重点关注结构和电重构。多项研究表明肥胖患者的消融结果较差。消融前体重减轻可改善结果,消融后维持体重减轻同样重要。风险因素修正计划显示出前景,然而它们需要大量资源投入。侧重于饮食和运动的强度较低的策略效果不一。胰高血糖素样肽-1受体激动剂已被确定为潜在的辅助治疗方法。它们具有多种作用,包括优先减少心外膜脂肪组织和抗炎作用。需要进一步研究以确定它们在改善消融结果方面的疗效。本综述强调体重管理在房颤治疗中的重要性,并提出使用心脏成像的潜在监测策略。未来的研究可能会改变对正在接受消融的肥胖房颤患者的管理模式。